Silence Therapeutics plc (LON:SLN) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.00 and traded as low as $82.50. Silence Therapeutics shares last traded at $84.00, with a volume of 151,122 shares trading hands.
Separately, Peel Hunt reissued a “buy” rating and issued a GBX 60 ($0.78) price target on shares of Renewi in a research note on Wednesday, July 3rd.
The company’s 50 day moving average is GBX 62.58. The stock has a market capitalization of $60.44 million and a price-to-earnings ratio of -3.20.
Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases.
Featured Story: The risks of owning bonds
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.